About this trial
The main goal of this study is to assess whether a mobile phone app called MiDiálisis is practical, easy to use, and well-accepted. The app was developed by the Technical University of Madrid (UPM) and is designed to bring together the clinical data of people with chronic kidney disease who are on peritoneal dialysis. This way, both patients and doctors can access the information at any time.
Eligibility criteria
Qualifiers
Patients over 18 years of age.
Patients with chronic kidney disease who have been on PD for at least 3 months in the same hospital.
Patients with a stable clinical condition during the 3 months prior to entering the study, defined as no unscheduled hospitalizations or major cardiovascular events (myocardial infarction or stroke) during that period.
Availability of a smartphone or tablet and internet access for the patient/caregiver.
Disqualifiers
Patients with limitations for multifrequency body composition measurement (pacemaker or implantable cardioverter defibrillator wearers, and pregnant women).
Patients who do not routinely use a smartphone or are unfamiliar with the use of mobile applications.
Patients who are scheduled for a living kidney transplant in the next 6 months.
Patients with a life expectancy of less than 6 months.
Trial design
Treatments tested in this trial
- Smart band
- Smart scale
- MiDialisis App
- Patients will install the app during the phase 2.
- Patients will connect the digital scale.
- Patients will connect the smartband.
Treatment groups
Sponsors and collaborators
Aida Frías González
Lead sponsor
Hospital Universitario 12 de Octubre
Sponsor institution
Spanish Society of Nephrology
Collaborator
SOMANE (MADRID SOCIETY OF NEPHROLOGY)
Collaborator
Foundation for Biomedical Research of the Hospital Universitario 12 de Octubre
Collaborator